<DOC>
	<DOCNO>NCT00412828</DOCNO>
	<brief_summary>This study evaluate safety , tolerability pharmacokinetics CR011-vcMMAE patient unresectable stage III stage IV melanoma fail 1 line prior cytotoxic therapy . CR011-vcMMAE administer intravenously ( IV ) every 3 week escalate dos maximum tolerate dose ( MTD ) reach . Once MTD define , 18-32 patient enrol evaluate safety efficacy CR011-vcMMAE dose level . Additional dosing schedule CR011-vcMMAE also explore .</brief_summary>
	<brief_title>A Phase I/II Study CR011-vcMMAE Subjects With Unresectable Stage III Stage IV Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female age ≥ 18 year . Progressive new metastatic melanoma , stage III IV . Measurable disease CT / MRI Failure 1 line prior cytotoxic therapy . Adequate bone marrow , renal hepatic function Leukocytes ≥ 3000/mm3 , ANC ≥ 1,500 cells/mm3 , Platelets ≥ 100,000/mm3 Hemoglobin ≥ 10 g/dL ( transfusion allow ) Total bilirubin ≤ 1.5 x upper normal limit ( UNL ) AST ( SGOT ) , ALT ( SGPT ) ≤ 3.0 x UNL ( ≤ 5.0 x UNL may acceptable ) Serum creatinine ≤ 1.5 mg/dL calculate creatinine clearance &gt; 45 mL/min/1.73 m2 PT/aPTT &lt; 1.5 x UNL within therapeutic range via anticoagulation therapy Karnofsky PS ≥ 70 % . Estimated life expectancy &gt; 3 month . Signed informed consent approve IRB ability comply study monitoring procedure . Subjects evaluable disease eligible doseescalation cohort Prior therapy disease study le 4 week prior enrollment . Major surgery trauma within 4 week enrollment . Active brain metastasis Active chronic inflammatory , autoimmunity , immunodeficiency disease , vascular hemorrhagic disorder . History allergic reaction dolastatin , auristatin compound similar composition . Significant cardiovascular disease Other malignancy Pregnancy breast feed Refusal inability use effective mean contraception ( men , woman childbearing potential ) History testpositive HIV , hepatitis B C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>CR011-vcMMAE</keyword>
</DOC>